CTOs on the Move


 
RDMD`s mission is to empower patients and communities to accelerate the development of treatments for rare diseases of all kinds.
  • Number of Employees: 25-100
  • Annual Revenue: $0-1 Million
  • www.rdmd.com
  • 121 2nd St
    San Francisco, CA USA 94105
  • Phone: N/A

Executives

Name Title Contact Details

Funding

RDMD raised $14M on 04/16/2020

Similar Companies

Syntimmune

Syntimmune approaches areas of high unmet medical need in a unique way. Instead of searching for novel, unproven disease biology, Syntimmune focuses on areas of science that are well understood and extensively researched. We seek new treatments that build on these areas of scientific consensus and broad applicability. In the case of our lead drug candidate, SYNT001, both the cellular pathway and the specific molecular target have been studied extensively for more than 25 years, spearheaded by the groundbreaking research of the scientific team behind Syntimmune. Building on proven areas of science enables Syntimmune to advance its drug candidates swiftly and predictably. The result is a significantly derisked approach to new drug development. More importantly, we believe our approach speeds approval of medicines for patients in areas where existing treatments involve inconvenience, dangerous side effects, or poor efficacy. In an industry that often places a premium on novelty, Syntimmune understands that creating real value comes from helping patients who are suffering with diseases for which current treatments are inadequate or nonexistent.

Molecular Therapeutics

Molecular Therapeutics is a Ann Arbor, MI-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Replimune

Replimune is creating a new class of oncolytic immunotherapy designed to ignite a powerful immune response to treat cancer and vaccinate against future relapse. Replimune`s mission is to revolutionize cancer treatment with therapies designed to activate a powerful and durable full-body anti-tumor response. Replimune is pioneering the development of novel tumor-directed oncolytic immunotherapies. We imagine a world where cancer is a curable disease.

Croda

Croda is a Edison, NJ-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

PepGen

Driven by our proprietary Enhanced Delivery Oligonucleotide (EDO) platform, we are creating a pipeline of disease-modifying therapeutics with the potential to safely and effectively target the root cause of serious genetic neuromuscular and neurological disorders.